Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Hodgkin's lymphoma Stories

2014-02-28 23:27:26

Mayo Clinic researchers say the identification of a mutated gene frequently found in Non-Hodgkin’s Lymphoma may open the door to new treatments. Raleigh, NC (PRWEB) February 28, 2014 A new report published in Blood Cancer Journal and detailed by the Non-Hodgkin’s Lymphoma Center finds that a high percentage of patients with Non-Hodgkin’s Lymphoma have a mutation on their MYD88 gene (MYD88L265P), which in turn can affect their immune system B-cells. B-cells or T-cells are the cells...

2014-02-27 04:20:49

- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE, Feb. 27, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published...

2014-02-24 23:26:06

Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) February 24, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article in the Journal of Photochemistry and Photobiology detailing a promising new treatment for people with cutaneous T-cell lymphoma (CTCL), a variety of T-cell Non-Hodgkin’s Lymphoma involving the skin. Patients...

2014-02-22 23:01:25

Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a newly-published article illustrating the potential dangers of rituximab therapy. Rituximab is a monoclonal antibody that is often used along with traditional chemotherapy in the treatment of Non-Hodgkin’s Lymphoma and other cancers involving the immune system B-cells....

2014-02-21 08:25:37

Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective...

2014-02-20 23:25:03

A European study of compounds designed to stimulate stem cells finds that biologically similar versions work as well as the original. Raleigh, NC (PRWEB) February 20, 2014 A study published in the journal Theranostics and reported by the Non-Hodgkin’s Lymphoma Center finds that a class of drugs that stimulate stem cell production in patients and donors is safe to use. The drugs are biologically similar to granulocyte colony stimulating factor (G-CSF), a human glycoprotein that...

2014-02-12 16:25:59

HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA(TM) (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) IMBRUVICA was first approved in November 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.(1) Both indications are based...

2014-02-03 10:31:39

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as non-Hodgkin's lymphomas). The results of the study were published today in...

2014-01-24 12:23:26

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera(®) (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2014-01-23 16:24:44

Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan. 23, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the fourteen researchers who will receive funding through the Quest for Cures program - a new grant program that addresses three critical areas of blood cancer research. The three priority areas are: monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular...